DESTINY-Breast03 Phase 3 Study Results
Overall Health Status and QOL on Treatment
Worse 70
DESTINY-Breast03
Daiichi-Sankyo
Ο
GHS
60
-40
-50
Better
GHS
Mean (SE) Change From
Baseline in EORTC QLQ-C30 GHS
T-DXd
50
40
30
20
10
considered clinically
meaningful
A 10-point change is
Mean (SD) change
from baseline at EOT
Min, Max
T-DM1
1.98 (21.340) 4.07 (22.048)
-50.0, 66.7
-75.0, 58.3
• As of May 21, 2021, patients still
receiving study drug included:1
•
⚫ T-DXd: 132 (51.4%)
0
HOH
-30
Treatment
T-DXd (baseline, n = 252)
T-DM1 (baseline, n = 259)
C17D1
C9D1
C11D1
C13D1
C15D1
C7D1
C5D1
C3D1
C2D1
C31D1
C29D1
C27D1.
C25D1
C23D1
C21D1
C19D1
Nominal Time Point (visits)
C, cycle; D, day; EORTC, European Organization for Research and Treatment of Cancer; EOT, end of treatment; GHS, global health scale; QLQ-C30, Quality of Life Core 30
questionnaire; QoL, quality of life; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
ESMO BC 2022 #1630 Oral
Scores range from 0 to 100; a linear transformation was applied to the raw GHS score, thus a higher score represents lower ("worse") GHS/overall QoL
1. Cortés J et al. Presented at: ESMO Virtual Congress 2021; September 16-21, 2021. Presentation 2525. 2. Cortés J et al. N Engl J Med. 2022;386:1143-1154.
C33D1
C35D1
C41D1
C39D1
C37D1
T-DM1
n < 20
T-DXd
n < 20
•
•
•
T-DXd: 14.3 (0.7-29.8) months
T-DM1: 6.9 (0.7-25.1) months
Global health was maintained in
patients treated with T-DXd while
on treatment (until n < 20 when
results are no longer informative)
•
T-DM1: 47 (18.0%)
•
Median (range) treatment duration:²
42View entire presentation